New research published using YINGCHI TMS

Chinese professional team published their latest research results in "PAIN", a leading journal in the field of pain. In the process of experiment, rTMS stimulation was performed by the YINGCHI FDA-approved M-100 Ultimate.

This study investigates the opioid peptide analgesic mechanism of prolonged continuous theta burst stimulation (pcTBS). The study was a randomized, double-blind, sham-controlled study to reveal whether the endogenous opioid system is involved in the analgesic effects induced by stimulation of the primary motor cortex (M1) and dorsal lateral prefrontal cortex (DLPFC) by intravenous administration of naloxone, an antagonist of the opioid receptor. The results showed that naloxone reversed the analgesic effects induced by stimulation of the primary motor cortex (M1) and dorsal lateral prefrontal cortex (DLPFC).

More information

New research published using YINGCHI TMS

Details

Feng Huang Cheng Da Sha, 科技园 Nan Shan Qu, Shen Zhen Shi, Guang Dong Sheng, China, 518057

Shenzhen Yingchi Technology

Associated Trend items

YINGCHI TMS | Welcome to visit us in MEDICA 2023

With over 5,000 exhibitors from 66 countries and more than 81,000 visitors from all over the world, MEDICA in Düsseldorf is one of the largest medical B2B trade fairs in the world.

As an old friend, YINGCHI will once again participate in MEDICA 2023. We are committed to allowing more people to obtain high-quality medical services, and always adheres to independent research and development and technological research.

More information

YINGCHl Asia Business Partners Meeting 2024

Thanks to our partners again for the support and participation in this conference, and hope to have better and long-term friendly communications, mutual assistance and benefit in the future.

In order to expend the distributors' knowledge of TMS and more understanding of YINGCHI TMS device, so as to deal with and solve related problems more effectively, and to consolidate the friendly cooperative relationship with our partners, our company held the 2024 Asia Business Partner Meeting at the beginning of March, some partners from Asia actively participated. Th...

More information

YINGCHI M-Ultimate TMS is cleared by FDA for MDD treatment!

We are glad to announce that YINGCHI M-Ultimate transcranial magnetic stimulator has already gained FDA approval this September.

As YINGCHI TMS device gains wider adoption in the medical community, it is expected to play a crucial role in the ongoing battle against depression. This FDA clearance is a testament to YINGCHI’s commitment to developing innovative solutions for mental health challenges. We are dedicated to providing patients with access to safe, non-invasive, and effective treatments fo...

More information

Products associated

TMS + rTMS transcranial magnetic stimulator

Compare up to 10 products

#Industry News

New research published using YINGCHI TMS

Associated Trend items

Products associated

M-series

Sham

E-series